Granted Patent
B2
US 8,343,491 · App. 12/518,857 · Granted Jan 1, 2013
Anti-HIMF antibodies to treat lung diseases
Assignee:
The Johns Hopkins University
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Hypoxia induced mitogenic factor (HIMF) is a member of the “found in inflammatory zone” (FIZZ)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. We use antibodies to HIMF to treat certain diseases including adult respiratory distress syndrome, radiation-induced pulmonary fibrosis, idiopathic pulmonary fibrosis, and emphysema.
Claims (3)
1. A method of treating a patient with Emphysema comprising:
administering to the patient an antibody which specifically binds to HIMF (SEQ ID NO:1 or 2);
whereby binding of HIMF to BTK is inhibited.
Assignments (3)
CONFIRMATORY LICENSE
Recorded May 30, 2019
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 049316/0326 →
CONFIRMATORY LICENSE
Recorded Oct 27, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044309/0543 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 13, 2009
From: JOHNS, ROGER A; SU, QINGNING; CHAMPION, HUNTER CLAY
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 023097/0848 →
Continuity (2)
Provisional Application
60875504
· Dec 18, 2006